Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Prothena Corporation plc - Ordinary Shares (NQ:PRTA)

5.410 +0.350 (+6.92%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 6, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Prothena Corporation plc - Ordinary Shares

< Previous 1 2 3 4 5 6 7 Next >
Williams Companies To Rally Over 11%? Here Are 10 Top Analyst Forecasts For Wednesday
Via Benzinga
Here are the top movers in Tuesday's session.
Here are the top movers in Tuesday's session, showcasing the stocks with significant price changes. 
Via Chartmill
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
Let's have a look at the top gainers and losers in the middle of the day of today's session.
Wondering how the US markets performed in the middle of the day on Tuesday? Discover the movers and shakers of today's session in our comprehensive analysis. 
Via Chartmill
Earnings Scheduled For May 8, 2025
Via Benzinga
A Look Ahead: Prothena Corp's Earnings Forecast
Via Benzinga
There are notable gap-ups and gap-downs in today's session.
In today's session, there are notable price gaps in the US markets on Tuesday. Take a closer look at the stocks that are gap up and gap down. 
Via Chartmill
PTC Therapeutics To Rally Around 61%? Here Are 10 Top Analyst Forecasts For Tuesday
Via Benzinga
Expert Outlook: Prothena Corp Through The Eyes Of 5 Analysts
Via Benzinga
Stay updated with the stocks that are on the move in today's pre-market session.
Before the US market kicks off on Tuesday, let's examine the pre-market session and unveil the notable performers among the top gainers and losers. 
Via Chartmill
Prothena Corp Stock: A Deep Dive Into Analyst Perspectives (9 Ratings)
Via Benzinga
Earnings Scheduled For February 20, 2025
Via Benzinga
Deep Dive Into Prothena Corp Stock: Analyst Perspectives (5 Ratings)
Via Benzinga
PDD Holdings Posts Weak Results, Joins EHang Holdings And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Why Is Prothena Stock Trading Lower On Tuesday?
Prothena halts birtamimab development after Phase 3 trial fails to meet endpoints in AL amyloidosis patients; cost cuts and new focus expected. 
Via Benzinga
US Stocks Likely To Open Higher After S&P 500's Four-Day Fall: 'Market Is Risk-Off,' Says Expert
U.S. stock futures rose on Tuesday after closing lower for the week on Friday. Futures of benchmark indices were trading higher in premarket. 
Via Benzinga
Topics Stocks
Exposures US Equities
Demystifying Prothena Corp: Insights From 6 Analyst Reviews
Via Benzinga
Why E2open Shares Are Trading Higher By 25%; Here Are 20 Stocks Moving Premarket
Via Benzinga
These stocks are moving in today's after hours session
As the regular session of the US market on Monday comes to an end, let's delve into the after-hours session and discover the top gainers and losers shaping the post-market sentiment. 
Via Chartmill
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
Top movers in Friday's after hours session
As the regular session of the US market on Friday comes to an end, let's delve into the after-hours session and discover the top gainers and losers shaping the post-market sentiment. 
Via Chartmill
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
Beyond The Numbers: 7 Analysts Discuss Prothena Corp Stock
Via Benzinga
Top 3 Health Care Stocks That Are Preparing To Pump This Quarter
Via Benzinga
CrowdStrike To Rally Over 18%? Here Are 10 Top Analyst Forecasts For Wednesday
Via Benzinga
Why IMAC Holdings Shares Are Trading Higher By Over 108%; Here Are 20 Stocks Moving Premarket
Via Benzinga
This S&P Global Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday
Via Benzinga
Topics Stocks
Exposures US Equities
Prothena Catapults, Flashing A Bullish Sign, On Promise In Parkinson's Disease
The drug technically missed the study's primary goal. But there's still promise it could work in specific patients. 
Via Investor's Business Daily
Roche-Prothena Partnered Mid-Stage Parkinson's Trial Misses Primary Endpoint, But Cling On Signs Of Clinical Benefits
Prothena and Roche report Phase 2b PADOVA results on prasinezumab in Parkinson's, showing promising trends and nominal significance in key analyses. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.